Implantation site intermediate trophoblasts in placenta cretas.
Placenta cretas are defined as abnormal adherences or ingrowths of placental tissue, but their pathogenetic mechanism has not been fully explained. During histologic examination of postpartum uteri, we noticed that the number of implantation site intermediate trophoblasts was increased in the placental bed of placenta cretas. To validate our observation and to address the pathogenetic role of implantation site intermediate trophoblasts in placenta cretas, we examined postpartum uteri with placenta cretas (n=34) and noncretas (n=22), obtained from Cesarean or immediate postpartum hysterectomy specimens. Using antibody to CD146, a marker for implantation site intermediate trophoblasts, we found that placenta cretas had significantly thicker layer of implantation site intermediate trophoblasts (2300+/-1200 mum) than noncretas (1500+/-1200 microm, P<0.025). We also observed that the confluent distribution of cells was more frequent in placenta cretas (97%) than noncretas samples (45%, P<0.001), and that the total number of implantation site intermediate trophoblasts within the superficial myometrium of the placental bed was significantly higher in placenta cretas than noncretas. Using antibodies to Ki-67, Bcl-2 and cleaved caspase-3 to determine the proliferative index and apoptotic rates of implantation site intermediate trophoblasts, we found that they were close to zero in both groups and did not differ significantly. These findings suggest that the increased number of implantation site intermediate trophoblasts observed in placenta cretas may be related to the pathogenesis of placental ingrowth, but the mechanism by which the increase in implantation site intermediate trophoblasts causes placenta cretas remains to be clarified.
Kim
Kyu-Rae
KR
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. krkim@amc.seoul.kr
Jun
Sun-Young
SY
Kim
Ji-Young
JY
Ro
Jae Y
JY
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D051929:CD146 Antigen; D053148:Caspase 3; D020169:Caspases / Q000032:analysis / Q000378:metabolism; D010064:Embryo Implantation; D005260:Female; D005865:Gestational Age; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D009215:Myometrium / Q000737:chemistry / Q000473:pathology; D019006:Neural Cell Adhesion Molecules / Q000032:analysis; D010920:Placenta / Q000737:chemistry / Q000473:pathology*; D011247:Pregnancy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D018245:Trophoblastic Tumor, Placental Site / Q000378:metabolism / Q000473:pathology; D014327:Trophoblasts / Q000737:chemistry / Q000473:pathology*; D014594:Uterine Neoplasms / Q000378:metabolism / Q000473:pathology
D015703:Antigens, CD; D051929:CD146 Antigen; D019394:Ki-67 Antigen; C497902:MCAM protein, human; D019006:Neural Cell Adhesion Molecules; D019253:Proto-Oncogene Proteins c-bcl-2; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases